Board to approve September 2026 quarterly results

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.8%Reaction day

₹70.53

prior close

—

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 170sector+0.6%+5.2% vs sector

On the reaction day the stock moved 5.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.8pendingpending+0.6+5.2

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board will meet on 3 November 2026 to approve the company's unaudited results for the quarter ended 30 September 2026. Trading by designated persons is closed from 1 October until 48 hours after the results are announced. The filing gives no revenue, profit, debt or cash flow figures.

Likely market impact

No financial figures are disclosed, so the stock impact cannot yet be assessed. The results announcement on 3 November is the next key information point.